Athersys stem cell therapy for COVID-19 targets the major causes of severe outcomes. This article explains the science, real evidence, patient safety considerations, and who may benefit—without overpromising or skipping real limits.
Athersys stem cell therapy is being investigated as a supportive treatment for the severe lung inflammation and immune overactivation seen in advanced COVID-19, known as acute respiratory distress syndrome (ARDS). Early clinical studies focus on whether these mesenchymal stem cells (MSCs), delivered intravenously, can modulate the immune response and reduce the risk of organ failure—the main cause of death in critical COVID-19 cases. This approach remains investigational across most jurisdictions and is not considered a guaranteed or routine part of COVID-19 care.
Many COVID-19 patients and families have faced devastating outcomes: prolonged hospital stays, intensive care, and, in the most severe cases, the loss of loved ones. Standard treatments sometimes fall short, especially for patients with severe lung inflammation or 'cytokine storm.' When conventional therapies seem limited, people seek new options that might offer a chance at better recovery—or a way to avoid ventilation. Questions often arise about new therapies, including Athersys' MultiStem, particularly after headlines about FDA designations or new approvals.
The main cause of death in severe COVID-19 is acute respiratory distress syndrome (ARDS), a rapid-onset inflammation of the lungs leading to low oxygen, mechanical ventilation, and multi-organ failure. ARDS is not unique to COVID-19 but became a global focus during the pandemic. The immune system's overreaction—sometimes called a 'cytokine storm'—damages lung tissue as much as, or more than, the virus itself. Preventing or limiting this overreaction is a major target for supportive therapies.
Athersys' approach uses mesenchymal stem cells (MSCs), specifically their MultiStem product, to potentially calm the immune response and promote repair in lung injury. MSCs are known for their immunomodulatory effects—releasing anti-inflammatory factors like TGF-β, VEGF, and exosomes capable of influencing neighboring cells (paracrine signaling). These properties might reduce lung inflammation, help restore lung tissue, and limit the need for mechanical ventilation. The cells themselves are typically administered via intravenous infusion in a hospital setting.
Immunomodulation refers to the ability of MSCs to shift an overactive immune system back toward balance—reducing damaging inflammation without shutting down needed defense against infection. This is very different from standard anti-inflammatory drugs, which can dampen immunity more broadly.
Clinical trials since 2020 have tested intravenous MSC infusions in patients with COVID-19-induced ARDS. Some studies report that MSCs may reduce markers of inflammation, improve oxygenation, and possibly shorten ICU stays for a subset of patients. However, published results also note that not every trial has demonstrated significant improvements in survival or long-term function. As of 2026, the best evidence suggests a potential supportive role for MSCs in severe COVID-19, but they are not a guaranteed solution—and are not a replacement for conventional intensive care.
MSCs, including Athersys' MultiStem, have not shown consistent survival benefit in every clinical trial for COVID-19 ARDS. There is no proof of disease cure or guaranteed improvement in lung function. Long-term outcomes, safety in high-risk populations, and how best to select candidates are still being actively researched. The role of stem cells in post-COVID lung fibrosis or other chronic complications is also unknown.
Potential candidates are typically adults hospitalized with moderate to severe COVID-19-induced ARDS, not responding adequately to standard care. Exclusion criteria often include active malignancy, uncontrolled infections, pregnancy, or advanced multi-organ failure. Each patient must be individually evaluated—MSC therapy is not for everyone, and contraindications must be taken seriously.
In our Istanbul clinic, the process begins with a remote or in-person medical review—analyzing case history, oxygen needs, recent labs, and previous treatments. If the patient is clinically stable enough for transfer, we coordinate hospital admission under Turkish Medicines and Medical Devices Agency (TİTCK) oversight. Non-Turkish international patients are treated under the international patient protocol—no separate Ministry of Health permit is needed. Turkish citizens require an individual Ministry of Health permit for cell therapies.
Our clinic uses umbilical cord-derived MSCs, obtained from ethically consented donors and processed in a GMP-aligned lab. Donor tissue is screened for HIV, HBV, HCV, CMV, EBV, mycoplasma, and bacterial endotoxins. Cell identity is confirmed by CD73/CD90/CD105 markers. Each manufactured lot is quality checked for sterility, viability, and documented lineage—ensuring only safe, potent cells are used. All procedures are physician-supervised and reviewed in a multidisciplinary team.
Most patients notice changes—if any—over several weeks to months. Some trials reported improvements in oxygenation or shorter ICU stays, but these benefits did not occur for every patient. Therapy is not a replacement for intensive hospital care. Some patients stabilize; others do not respond. Long-term function can depend on age, baseline health, and timing of the intervention.
Risks include infusion reactions, infection risk, theoretical concerns about clotting or immune suppression, and—rarely—worsening of underlying organ dysfunction. The overall safety profile of intravenous MSCs is considered acceptable in published trials, but not without risk. Unregulated or poorly documented stem cell products may carry additional dangers. This is not a guaranteed or side-effect-free procedure; open discussion with the treating team is critical.
Patients considering MSC therapy in Istanbul should plan for a minimum hospital stay of 7–14 days (often longer, depending on severity). English-speaking coordinators assist with travel, transfer, local support, and follow-up. All treatment is under physician supervision and TİTCK regulatory oversight. Aftercare, including telemedicine follow-up, is arranged according to patient's health and recovery status.
Athersys stem cell therapy remains investigational in most countries, including the US, UK, EU, and Australia. That means it is not routinely available as a standard covered treatment—and is only accessed through clinical trials, special access, or regulated overseas protocols. Although the therapy is not 'illegal' for you to receive abroad, insurance or government health systems rarely reimburse it. Always confirm the regulatory status for your specific country and clinic.
Conventional care addresses oxygen support, ventilation, steroids, and antiviral drugs. Stem cell therapy aims to modulate the immune response and support tissue repair from a different angle. It's an adjunct, not a replacement—and has not replaced established ICU or respiratory medicine care.
No high-quality human trial has yet proven a benefit for chronic 'long COVID' fatigue, pulmonary fibrosis, or other post-infection sequelae. MSC therapy is mainly studied for acute ARDS in the hospital phase, not as a solution for lingering post-COVID symptoms.
Suitability depends on severity, timing, exclusion criteria, and clinical history. Anyone considered for MSC therapy should have a thorough case review—including current organ function, infection status, cancer history, and prognosis—by a qualified specialist. Not every critically ill patient is eligible or likely to benefit.
We require recent hospital notes, imaging (e.g., CT scans), ICU or respiratory status, current medications, lab tests, and a timeline of illness progression. This assessment helps define if MSC therapy is safe, feasible, and medically appropriate for your individual circumstance.
No responsible provider can promise a cure or guaranteed improvement. The best available evidence indicates some patients may benefit while others see limited or no change. MSC therapy is part of experimental, physician-led protocols, not a universal lifeline.
Ask about regulatory compliance (e.g., TİTCK oversight), cell source documentation, clinical protocols, monitoring, published outcomes, adverse event rates, and realistic timelines for assessment and care. Transparent clinics will answer these directly.
Urgent or deteriorating patients should not delay proven ICU and respiratory support in hopes of traveling. If the patient is unstable or rapidly declining, staying local for critical care is safer in nearly all cases. International transfer is only appropriate for select, stable cases.
International patients can access MSC therapy under Turkish regulation (TİTCK); Turkish citizens require additional Ministry of Health permission for cell therapies. Every case is closely monitored under multidisciplinary oversight, following GMP and documented product standards. It remains the patient's responsibility to understand how these regulations differ from those in their home country, and to seek clarification before proceeding. This article is intended for patient education and international medical orientation. It does not replace medical, legal, or regulatory advice in your home country. MSC and exosome-based treatments are regulated differently across jurisdictions, and individual suitability must always be assessed by a qualified physician.
Athersys Stem Cell Therapy and the Top Cause of COVID-19 Deaths: Patient Evidence, Safety, and Candidacy in 2026